Application of Gene-Based Therapy in Animal Model of Glaucoma

In this AGS 2017 presentation, Dr. Andras M. Komaromy discusses findings on gene therapy for glaucoma in a dog model. Previously, Dr. Komaromy assisted in the preclinical development of retinal gene therapy for Leber congenital amaurosis, which demonstrated the viability of the dog model for ocular diseases. His group is currently evaluating a proof-of-concept Adeno-associated virus (AAV) vector gene replacement therapy for a mutation that causes overexpression of a metalloproteinase in the trabecular meshwork of dogs with open-angle glaucoma. The therapy has shown promise for sustained reduction of IOP.